2022-001067-27
A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA
Pdf
Stampa
W06 Ricerca farmaco
Titolo/oggetto del contratto di sperimentazione
A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA
Codice EUDRACT
2022-001067-27
Promotore
Bayer Spa
Codice del protocollo del promotore
20604 (BAY 2433334 Oceanic Stroke)
Data di nullaosta
06-02-2023
Data sottoscrizione del contratto
15-02-2023
Data di chiusura
Budget
4.190,00
Rimborsi
0,00
Totale
4.190,00
note
Data ultima modifica
02-03-2023 15:30:52
Pincipal investigators
Nome Unità Operativa
Neurologia di Cesena
Nome principal investigator
Marco Longoni
Principal investigator
CV Principal investigator